Detrusin1 mg

Detrusin is an antimuscarinic (anticholinergic) agent approved for the treatment of overactive bladder (OAB).

Established / FDA-approved use

• Treatment of overactive bladder in adults with symptoms of urinary urgency, frequency, and urge incontinence.

Detrusin is not indicated for stress urinary incontinence or for children, and it has no established role as an adjunct or combination therapy for other conditions.

Each unit of Tolterodine Tartrate contains tolterodine tartrate as the active pharmaceutical ingredient, formulated as:

• Immediate-release (IR) tablets — commonly 1 mg and 2 mg strengths.
• Extended-release (ER) capsules — commonly 2 mg and 4 mg strengths.

Excipients vary by manufacturer and formulation; refer to the specific product label for the complete inactive ingredient list.

Detrusin is a synthetic muscarinic receptor antagonist used to reduce the involuntary contractions of the urinary bladder that cause overactive bladder symptoms. It is available as an immediate-release tablet, dosed twice daily, and as an extended-release capsule, dosed once daily.

Detrusin does not cure overactive bladder but helps control its symptoms as long as treatment continues; ongoing use should be reviewed periodically with a physician.

Detrusin belongs to the antimuscarinic (anticholinergic) urinary antispasmodic class of drugs, used specifically for bladder overactivity.

Mechanism of action

Tolterodine Tartrate is a competitive antagonist at muscarinic acetylcholine receptors (predominantly M2 and M3 subtypes) found on bladder detrusor smooth muscle. By blocking acetylcholine-mediated stimulation of these receptors, Tolterodine Tartrate reduces involuntary detrusor muscle contractions, thereby increasing bladder capacity and reducing urgency, frequency, and urge incontinence episodes.

Pharmacokinetics

Tolterodine Tartrate is extensively metabolized in the liver, primarily via CYP2D6 to an active metabolite (5-hydroxymethyl tolterodine) with a pharmacologic activity similar to the parent drug, and to a lesser extent via CYP3A4. Elimination is mainly renal and hepatic. Individuals who are poor CYP2D6 metabolizers rely more heavily on the CYP3A4 pathway and may have higher exposure to unmetabolized Tolterodine Tartrate, which is relevant when combined with CYP3A4 inhibitors.

Detrusin extended-release capsules should be swallowed whole with water and must not be chewed, crushed, or opened. Detrusin immediate-release tablets may be taken with or without food, at consistent times each day (approximately 12 hours apart). If a dose is missed, it should be taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped — doses should not be doubled.

Strong CYP3A4 or CYP2D6 inhibitors

Co-administration of Detrusin with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) or potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can significantly increase plasma levels of Detrusin. When Detrusin is used with a strong CYP3A4 inhibitor, the lower recommended dose should be used.

Other anticholinergic (antimuscarinic) drugs

Concurrent use of Detrusin with other anticholinergic medications (e.g., other bladder antimuscarinics, certain antihistamines, tricyclic antidepressants) can produce additive anticholinergic effects such as dry mouth, constipation, blurred vision, and confusion, particularly in elderly patients.

QT-prolonging drugs

Detrusin has a dose-related effect on cardiac repolarization (QT interval). Combining Detrusin with other drugs known to prolong the QT interval, or use in patients with pre-existing QT prolongation or relevant risk factors, may increase the risk of ventricular arrhythmia; such combinations require caution and, where possible, avoidance.

The most common adverse effect of Detrusin, consistent with its anticholinergic mechanism, is:

• Dry mouth (very common)
• Constipation
• Blurred vision / accommodation difficulty
• Dizziness
• Headache
• Dry eyes
• Dyspepsia / abdominal discomfort
• Urinary retention (uncommon, more likely with pre-existing bladder outlet obstruction)

Less common but clinically important effects

Detrusin can cause a dose-related prolongation of the QT interval (see Interactions and Precautions). Confusion, memory impairment, and other cognitive effects have been reported, particularly in elderly patients, due to the drug's anticholinergic burden.

Data on the use of Detrusin in human pregnancy are limited. Detrusin should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus. It is not known whether Detrusin is excreted in human breast milk; a decision should be made whether to discontinue breastfeeding or discontinue the drug, taking into account the benefit of breastfeeding and the mother's clinical need for treatment. A physician should always be consulted before use of Detrusin during pregnancy or breastfeeding.

Anticholinergic burden in the elderly

Detrusin should be used with caution in elderly patients, who may be more susceptible to anticholinergic central nervous system effects such as confusion, memory impairment, and falls risk, especially when combined with other anticholinergic medications.

Reduced gastrointestinal motility

Use Detrusin with caution in patients with conditions associated with decreased gastrointestinal motility, such as severe constipation, due to the risk of gastric retention.

Myasthenia gravis

Detrusin may worsen symptoms of myasthenia gravis and should be used with caution in these patients.

Bladder outlet obstruction

Detrusin should be used with caution in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.

QT prolongation / cardiac risk

Detrusin produces a dose-related increase in the QT interval. Caution is warranted in patients with congenital or acquired QT prolongation, relevant electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), or when combined with other QT-prolonging drugs (see Interactions).

Hepatic and renal impairment

Dose reduction of Detrusin is recommended in significant hepatic or renal impairment (see Dosage and Administration).

Heat prostration

As with other anticholinergic drugs, Detrusin may decrease sweating, and use in a hot environment can result in heat prostration.

Ability to drive or operate machinery

Detrusin may cause blurred vision, dizziness, or somnolence; patients should be cautious about driving or operating machinery until they know how they respond to treatment.

Overdose with Detrusin may result in exaggerated anticholinergic effects such as severe dry mouth, blurred vision, urinary retention, agitation, and, notably, QT prolongation or cardiac arrhythmia due to its dose-related cardiac repolarization effect. There is no specific antidote for Detrusin overdose.

In case of a suspected overdose, seek immediate medical attention or contact a poison control center right away. ECG monitoring may be warranted because of the risk of QT prolongation. Treatment is supportive and symptomatic and should be managed by qualified medical personnel; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

No overall dose adjustment of Detrusin is required based on age alone, but elderly patients may be more sensitive to anticholinergic adverse effects (e.g., confusion, constipation), so caution and monitoring are advised.

Renal impairment

A lower dose of Detrusin is recommended in patients with significantly reduced renal function (see Dosage and Administration).

Hepatic impairment

A lower dose of Detrusin is recommended in patients with significant hepatic impairment (see Dosage and Administration).

Pediatric population

Safety and efficacy of Detrusin have not been established in children; it is not recommended for use in this population.

Pregnancy and lactation

See Pregnancy and Lactation section — use only if clearly needed, under medical supervision.

The duration of Detrusin treatment should be individualized based on symptom response, generally assessed after 2 to 3 months of therapy. Detrusin controls symptoms of overactive bladder but does not cure the underlying condition, so ongoing treatment should be periodically reviewed with the prescribing physician to confirm continued benefit and tolerability.

Antimuscarinics; Urinary antispasmodics; Overactive bladder agents

Tolterodine Tartrate acts as a competitive muscarinic receptor antagonist, blocking M2 and M3 muscarinic acetylcholine receptors on the detrusor smooth muscle of the urinary bladder. This antagonism inhibits acetylcholine-induced detrusor contraction, reducing involuntary bladder muscle spasms, increasing functional bladder capacity, and thereby decreasing the frequency and urgency of urination as well as episodes of urge incontinence.

C

The safety and effectiveness of Detrusin in pediatric patients have not been established. Detrusin is not recommended for use in children, and no approved pediatric dosing exists.